Development of a Silicon Phthalocyanine Analogue for Near-Infrared Photoimmunotherapy and its Application to HTLV-1-infected Leukemic Cells

Key Points

• Enhanced efficacy of photoimmunotherapy was achieved using a silicon phthalocyanine analogue in leukemic cells.
• The primary assessment revealed significant treatment effects in cancer cells when using the IR700 dye in combination.
• This analysis utilized an innovative approach to develop a silicon phthalocyanine analogue for targeted cancer therapy.
• These findings highlight promising implications for combining silicon phthalocyanine with antibodies in cancer treatments.